A Network Pharmacology Approach to Uncover the Multiple Mechanisms of Willd. on Colorectal Cancer

Overview

Journal Evid Based Complement Alternat Med

Specialty Rehabilitation Medicine

Date 2018 Apr 6

PMID 29619072

Citations 33

Authors

Xinkui Liu

Jiarui Wu

Dan Zhang

Kaihuan Wang

XiaoJiao Duan

Xiaomeng Zhang

Affiliations

Soon will be listed here.

Abstract

Background: As one of the most frequently diagnosed cancer diseases globally, colorectal cancer (CRC) remains an important cause of cancer-related death. Although the traditional Chinese herb Willd. (HDW) has been proven to be effective for treating CRC in clinical practice, its definite mechanisms have not been completely deciphered.

Objective: The aim of our research is to systematically explore the multiple mechanisms of HDW on CRC.

Methods: This study adopted the network pharmacology approach, which was mainly composed of active component gathering, target prediction, CRC gene collection, network analysis, and gene enrichment analysis.

Results: The network analysis showed that 10 targets might be the therapeutic targets of HDW on CRC, namely, HRAS, PIK3CA, KRAS, TP53, APC, BRAF, GSK3B, CDK2, AKT1, and RAF1. The gene enrichment analysis implied that HDW probably benefits patients with CRC by modulating pathways related to cancers, infectious diseases, endocrine system, immune system, nervous system, signal transduction, cellular community, and cell motility.

Conclusions: This study partially verified and predicted the pharmacological and molecular mechanism of HDW against CRC from a holistic perspective, which will also lay a foundation for the further experimental research and clinical rational application of HDW.

Citing Articles

Network pharmacology and experimental verification unraveled the mechanism of Bailing Capsule against asthma.

Lin S, Chen M, Lin S, Huang X, Chen W, Wu S Medicine (Baltimore). 2024; 103(44):e40391.

PMID: 39495985 PMC: 11537631. DOI: 10.1097/MD.0000000000040391.

Exploring the anticancer potential of : A systematic network pharmacology study on lung cancer.

Mutiah R, Rachmawati E J Adv Pharm Technol Res. 2024; 15(1):49-55.

PMID: 38389971 PMC: 10880913. DOI: 10.4103/JAPTR.JAPTR_334_23.

The Potential of Eleutherine bulbosa in Inducing Apoptosis and Inhibiting Cell Cycle in Breast Cancer: A Network Pharmacology Approach and In Vitro Experiments.

Milliana A, Listiyana A, Mutiah R, Annisa R, Firadusi A, Faradila V Asian Pac J Cancer Prev. 2023; 24(11):3783-3794.

PMID: 38019236 PMC: 10772747. DOI: 10.31557/APJCP.2023.24.11.3783.

Hedyotis diffusa-Sculellaria barbata (HD-SB) suppresses the progression of colorectal cancer cells via the hsa_circ_0039933/hsa-miR-204-5p/wnt11 axis.

Zhu D, Yuan S, Chen C Sci Rep. 2023; 13(1):13331.

PMID: 37587207 PMC: 10432535. DOI: 10.1038/s41598-023-40393-1.

L. Polysaccharide Inhibits Porcine Rotavirus In Vitro.

Zhou X, Li Y, Li T, Cao J, Guan Z, Xu T Animals (Basel). 2023; 13(14).

PMID: 37508085 PMC: 10376577. DOI: 10.3390/ani13142306.

References

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

Aoki K, Taketo M . Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene. J Cell Sci. 2007; 120(Pt 19):3327-35. DOI: 10.1242/jcs.03485. View

Wang X, Shen Y, Wang S, Li S, Zhang W, Liu X . PharmMapper 2017 update: a web server for potential drug target identification with a comprehensive target pharmacophore database. Nucleic Acids Res. 2017; 45(W1):W356-W360. PMC: 5793840. DOI: 10.1093/nar/gkx374. View

Lee H, Bau D, Kuo C, Tsai R, Chen Y, Chang Y . Clarification of the phenotypic characteristics and anti-tumor activity of Hedyotis diffusa. Am J Chin Med. 2011; 39(1):201-13. DOI: 10.1142/S0192415X11008750. View

Cheok C, Verma C, Baselga J, Lane D . Translating p53 into the clinic. Nat Rev Clin Oncol. 2010; 8(1):25-37. DOI: 10.1038/nrclinonc.2010.174. View

Pinero J, Queralt-Rosinach N, Bravo A, Deu-Pons J, Bauer-Mehren A, Baron M . DisGeNET: a discovery platform for the dynamical exploration of human diseases and their genes. Database (Oxford). 2015; 2015:bav028. PMC: 4397996. DOI: 10.1093/database/bav028. View

Guo Y, Xiong B, Zhang T, Cheng Y, Ma L . XELOX vs. FOLFOX in metastatic colorectal cancer: An updated meta-analysis. Cancer Invest. 2016; 34(2):94-104. DOI: 10.3109/07357907.2015.1104689. View

Issa I, Noureddine M . Colorectal cancer screening: An updated review of the available options. World J Gastroenterol. 2017; 23(28):5086-5096. PMC: 5537177. DOI: 10.3748/wjg.v23.i28.5086. View

Szklarczyk D, Morris J, Cook H, Kuhn M, Wyder S, Simonovic M . The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res. 2016; 45(D1):D362-D368. PMC: 5210637. DOI: 10.1093/nar/gkw937. View

10.

Gu G, Barone I, Gelsomino L, Giordano C, Bonofiglio D, Statti G . Oldenlandia diffusa extracts exert antiproliferative and apoptotic effects on human breast cancer cells through ERα/Sp1-mediated p53 activation. J Cell Physiol. 2012; 227(10):3363-72. DOI: 10.1002/jcp.24035. View

11.

Gong J, Cho M, Fakih M . RAS and BRAF in metastatic colorectal cancer management. J Gastrointest Oncol. 2016; 7(5):687-704. PMC: 5056249. DOI: 10.21037/jgo.2016.06.12. View

12.

Deschoemaeker S, Di Conza G, Lilla S, Martin-Perez R, Mennerich D, Boon L . PHD1 regulates p53-mediated colorectal cancer chemoresistance. EMBO Mol Med. 2015; 7(10):1350-65. PMC: 4604688. DOI: 10.15252/emmm.201505492. View

13.

Chen Y, Yang Q, Kuang J, Chen S, Wei Y, Jiang Z . Efficacy of adding bevacizumab in the first-line chemotherapy of metastatic colorectal cancer: evidence from seven randomized clinical trials. Gastroenterol Res Pract. 2014; 2014:594930. PMC: 4058184. DOI: 10.1155/2014/594930. View

14.

MORGAN D . Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu Rev Cell Dev Biol. 1997; 13:261-91. DOI: 10.1146/annurev.cellbio.13.1.261. View

15.

Roy H, Olusola B, Clemens D, Karolski W, Ratashak A, Lynch H . AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis. Carcinogenesis. 2002; 23(1):201-5. DOI: 10.1093/carcin/23.1.201. View

16.

Oren M, Rotter V . Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol. 2010; 2(2):a001107. PMC: 2828285. DOI: 10.1101/cshperspect.a001107. View

17.

Hoeflich K, Luo J, Rubie E, Tsao M, Jin O, Woodgett J . Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature. 2000; 406(6791):86-90. DOI: 10.1038/35017574. View

18.

Samuels Y, Velculescu V . Oncogenic mutations of PIK3CA in human cancers. Cell Cycle. 2004; 3(10):1221-4. DOI: 10.4161/cc.3.10.1164. View

19.

Willimott S, Barker J, Jones L, Opara E . Apoptotic effect of Oldenlandia diffusa on the leukaemic cell line HL60 and human lymphocytes. J Ethnopharmacol. 2007; 114(3):290-9. DOI: 10.1016/j.jep.2007.08.030. View

20.

Shaw R, Cantley L . Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature. 2006; 441(7092):424-30. DOI: 10.1038/nature04869. View